In-Vitro Diagnostic Substance Manufacturing obligations, FY2025

NAICS 325413 joined with fiscal year 2025

The relationship is mechanical: NAICS 325413 crossed with fiscal year 2025 yields one obligation sum. $210,707,144.32 is that sum for In-Vitro Diagnostic Substance Manufacturing in 2025. USAspending.gov publishes the figure as a yearlyTrend obligation total. Obligations are commitments recorded on awards, not Treasury outlays. The industry-wide extract remains $1,876,000,543.48; the FY2025 hub remains a separate parent. This pair does not explain why agencies bought in-vitro diagnostic substance manufacturing on awards, and it does not name contractors or award recipients.

Nothing in the facts supports reading $210,707,144.32 as a count of kits, plants, or named makers. This page does not evaluate tests or name manufacturers. Correlation between this NAICS label and FY2025 spending is the join itself, not a causal story. Campaign-finance tables do not fund these USAspending obligations. Place-of-performance and awarding-agency splits are omitted from this packet.

Diagnostic-substance dollars inside FY2025

On the industry side, NAICS 325413 is the In-Vitro Diagnostic Substance Manufacturing extract. Its published total across the extract is $1,876,000,543.48. $210,707,144.32 sits inside that book at 11.2%; the other fiscal-year rows for the same code sum to $1,665,293,399.16 in this arithmetic. The parent industry page holds the longer series without isolating 2025. Award records in the extract number 5,683; that count is not limited to FY2025.

In-vitro diagnostic substance manufacturing on awards is the NAICS description attached to the awards, not a proof of goods delivered. A later USAspending ingest can restate $210,707,144.32 or $1,876,000,543.48 without changing the join keys. Do not add the all-industries index into this cell. The 11.2% share is $210,707,144.32 divided by $1,876,000,543.48, not a budget score or a ranking of industries.

5,683 records are not 5,683 kits

5,683 award records are not 5,683 units of kits, plants, or named makers. The count rides with the In-Vitro Diagnostic Substance Manufacturing extract, not with a FY2025-only slice. Modifications, deobligations, and multiple lines can inflate row counts. Unique recipients stay unpublished. A per-award mean from $210,707,144.32 and 5,683 would mix a FY2025 dollar total with an extract-wide record count. This packet does not publish a FY2025-only award-record count for NAICS 325413.

What this diagnostic-manufacturing cell omits

What the table is: USAspending.gov NAICS yearlyTrend for In-Vitro Diagnostic Substance Manufacturing (NAICS 325413) in fiscal year 2025, totaling $210,707,144.32. What the table is not: an outlay register, a product catalog, a lab directory, medical advice, an agency split, a map, or an FEC-funded pipeline. Public records, not accusations. This page does not evaluate tests or name manufacturers.

Do not treat 11.2% as evidence that FY2025 dominated in-vitro diagnostic substance manufacturing on awards in a causal sense. The share is arithmetic on two packet totals. Named contractors and award recipients are absent from the facts. Quote NAICS 325413, FY2025, and $210,707,144.32 together. The remainder of the extract after FY2025 is $1,665,293,399.16 in this arithmetic, still not an outlay.

Parents for NAICS 325413 and FY2025

Four hrefs ship with the packet: /industries/325413/ (NAICS 325413), /fiscal-years/2025/ (FY2025 federal spending), /industries/ (All industries), and /ties/ (All spending ties). Use them as parents, not as this cell. Original filings remain on USAspending.gov for this 325413 × FY2025 pair.

Keep In-Vitro Diagnostic Substance Manufacturing and FY2025 together when citing $210,707,144.32. NAICS 325413's extract-wide award-record count is 5,683, not a FY2025 census of kits, plants, or named makers. Obligations of $210,707,144.32 are not outlays. The 11.2% share uses the extract-wide $1,876,000,543.48 as the denominator. Agency and geography splits are omitted. A later ingest can restate $210,707,144.32 without changing NAICS 325413 or fiscal year 2025.

On the year side, fiscal year 2025 is the second join key. $210,707,144.32 is In-Vitro Diagnostic Substance Manufacturing inside FY2025, not all federal obligations recorded for that year. Other NAICS codes have their own FY2025 cells. The fiscal-year parent lists government-wide context without this industry filter. FY figures can be incomplete or later restated; the source note on this packet says so.

Keep In-Vitro Diagnostic Substance Manufacturing, NAICS 325413, FY2025, and $210,707,144.32 in one citation. Dropping the year turns the figure into the extract-wide $1,876,000,543.48. Dropping the NAICS turns it into a year hub that is not this join. Outlays remain unpublished here.

Questions

How much did In-Vitro Diagnostic Substance Manufacturing obligate in FY2025?

USAspending.gov records $210,707,144.32 in In-Vitro Diagnostic Substance Manufacturing obligations for fiscal year 2025 under NAICS 325413. That amount is a yearlyTrend obligation total, not an outlay and not the industry's $1,876,000,543.48 extract-wide sum. The join names both In-Vitro Diagnostic Substance Manufacturing and FY2025; it does not name contractors or award recipients.

Is $210,707,144.32 the entire NAICS 325413 USAspending total?

No. NAICS 325413's extract-wide total is $1,876,000,543.48. FY2025 is 11.2% of that book. Other fiscal-year rows for the same code are separate cells. Do not add the parent hub into this join. Obligations of $210,707,144.32 are not outlays. USAspending.gov remains the source for the 325413 × 2025 pair.

Do 5,683 awards equal 5,683 diagnostic kits in FY2025?

No. 5,683 is the In-Vitro Diagnostic Substance Manufacturing award-record count in this extract, not a FY2025-only census of kits, plants, or named makers. The packet does not split those records by fiscal year or name contractors. USAspending.gov remains the source. Unique recipients are unpublished on this join.

Do FEC filings explain In-Vitro Diagnostic Substance Manufacturing obligations in FY2025?

No. FEC filings do not explain $210,707,144.32. The source is USAspending.gov. Obligations are not outlays, and donations do not fund NAICS 325413 in FY2025. The pair is NAICS 325413 plus fiscal year 2025. Campaign-finance tables are a different dataset from this yearlyTrend cell.